Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

Timing of Initiation of Palliative Chemotherapy in Asymptomatic Patients with Metastatic Pancreatic Cancer: An International Expert Survey and Case-Vignette Study

Title: Timing of Initiation of Palliative Chemotherapy in Asymptomatic Patients with Metastatic Pancreatic Cancer: An International Expert Survey and Case-Vignette Study
Authors: Simone Augustinus; Hanneke W. M. van Laarhoven; Geert A. Cirkel; Jan Willem B. de Groot; Bas Groot Koerkamp; Teresa Macarulla; Davide Melisi; Eileen M. O'Reilly; Hjalmar C. van Santvoort; Tara M. Mackay; Marc G. Besselink; Johanna W. Wilmink
Source: Cancers, Vol 15, Iss 23, p 5603 (2023)
Publisher Information: MDPI AG
Publication Year: 2023
Collection: Directory of Open Access Journals: DOAJ Articles
Subject Terms: expert survey; case-vignette; pancreatic cancer; asymptomatic; timing of chemotherapy; Neoplasms. Tumors. Oncology. Including cancer and carcinogens; RC254-282
Description: Background : The use of imaging, in general, and during follow-up after resection of pancreatic cancer, is increasing. Consequently, the number of asymptomatic patients diagnosed with metastatic pancreatic cancer (mPDAC) is increasing. In these patients, palliative systemic therapy is the only tumor-directed treatment option; hence, it is often immediately initiated. However, delaying therapy in asymptomatic palliative patients may preserve quality of life and avoid therapy-related toxicity, but the impact on survival is unknown. This study aimed to gain insight into the current perspectives and clinical decision=making of experts regarding the timing of treatment initiation of patients with asymptomatic mPDAC. Methods : An online survey (13 questions, 9 case-vignettes) was sent to all first and last authors of published clinical trials on mPDAC over the past 10 years and medical oncologists of the Dutch Pancreatic Cancer Group. Inter-rater variability was determined using the Kappa Light test. Differences in the preferred timing of treatment initiation among countries, continents, and years of experience were analyzed using Fisher’s exact test. Results : Overall, 78 of 291 (27%) medical oncologists from 15 countries responded (62% from Europe, 23% from North America, and 15% from Asia–Pacific). The majority of respondents (63%) preferred the immediate initiation of chemotherapy following diagnosis. In 3/9 case-vignettes, delayed treatment was favored in specific clinical contexts (i.e., patient with only one small lung metastasis, significant comorbidities, and higher age). A significant degree of inter-rater variability was present within 7/9 case-vignettes. The recommended timing of treatment initiation differed between continents for 2/9 case-vignettes (22%), in 7/9 (77.9%) comparing the Netherlands with other countries, and based on years of experience for 5/9 (56%). Conclusions : Although the response rate was limited, in asymptomatic patients with mPDAC, immediate treatment is most often preferred. ...
Document Type: article in journal/newspaper
Language: English
Relation: https://www.mdpi.com/2072-6694/15/23/5603; https://doaj.org/toc/2072-6694; https://doaj.org/article/05a757ff63264a9c9e9dabdbfe5fa8bc
DOI: 10.3390/cancers15235603
Availability: https://doi.org/10.3390/cancers15235603; https://doaj.org/article/05a757ff63264a9c9e9dabdbfe5fa8bc
Accession Number: edsbas.EF3C5923
Database: BASE